Prognosis of patients with stage D1 prostatic adenocarcinoma.


Journal Article

Of 44 patients with clinically localized prostatic adenocarcinoma and regional lymphatic metastases proved by staging pelvic lymphadenectomy 11 were treated by radical prostatectomy, 20 received extended field radiation and 13 were assigned to delayed hormonal therapy. The median survival for the entire group was 39.5 months. None of the 3 treatments appeared superior in prolonging survival. Furthermore, no enhancement of disease control could be demonstrated in either treatment group. Patients with prostatic adenocarcinoma and positive nodes appear to have equivalent adverse biological potential and should be candidates for treatments designed to produce systemic effect.

Full Text

Duke Authors

Cited Authors

  • Kramer, SA; Cline, WA; Farnham, R; Carson, CC; Cox, EB; Hinshaw, W; Paulson, DF

Published Date

  • June 1981

Published In

Volume / Issue

  • 125 / 6

Start / End Page

  • 817 - 819

PubMed ID

  • 7241680

Pubmed Central ID

  • 7241680

International Standard Serial Number (ISSN)

  • 0022-5347

Digital Object Identifier (DOI)

  • 10.1016/s0022-5347(17)55217-9


  • eng

Conference Location

  • United States